Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;11(2):411-425.
doi: 10.1007/s13346-021-00940-7. Epub 2021 Feb 26.

Intranasal drug delivery for treatment of Alzheimer's disease

Affiliations
Review

Intranasal drug delivery for treatment of Alzheimer's disease

Leonor C Fonseca et al. Drug Deliv Transl Res. 2021 Apr.

Abstract

The Alzheimer's disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is characterized as a progressive and irreversible brain disorder hampering memory and thinking, affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation. The conventional treatment occurs by the oral route, but it presents relevant drawbacks such as low bioavailability, fast metabolism, limited brain exposure, and undesirable side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for drug intranasal delivery for Alzheimer's disease treatment. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.

Keywords: Blood-brain barrier; Central nervous system; Nanoparticle; Neurodegenerative; Permeation enhancer; Protein.

PubMed Disclaimer

References

    1. Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep. 2016;3391–6.
    1. Chapman CD, Frey WH, Craft S, Danielyan L, Hallschmid M, Schiöth HB, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30:2475–84. - PubMed
    1. Thies W, Bleiler L. Alzheimer’s disease facts and figures. Alzheimer’s Dement J Elsevier Ltd. 2013;9:208–45.
    1. Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106.
    1. Dufes C, Olivier J, Gaillard F, Gaillard A, Couet W, Muller J. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm. 2003;255:87–97. - PubMed

Publication types

Substances

LinkOut - more resources